Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
18 hedge funds and large institutions have $3.97M invested in Rosetta Genomics Ltd. in 2014 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 4 closing their positions.
734% more capital invested
Capital invested by funds: $476K → $3.97M (+$3.49M)
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
64% more funds holding
Funds holding: 11 → 18 (+7)
16% less call options, than puts
Call options by funds: $315K | Put options by funds: $375K
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$1.59M |
| 2 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
+$469K |
| 3 |
Jane Street
New York
|
+$275K |
| 4 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$204K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$162K |
| 2 |
OC
Oppenheimer & Co
New York
|
-$131K |
| 3 |
Morgan Stanley
New York
|
-$26.7K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$22.9K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$7.23K |
ROSG Hedge Fund Activity: Q1 2014 in Review
18 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q1 2014, worth a combined $3.97M — up 734% from $476K a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ROSG positions and 4 closed out — a net gain of 7 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was B. Riley Wealth Advisors, opening a new position worth an estimated $1.59M. The largest seller was Tower Research Capital (TRC), cutting an estimated $162K.
- 18 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q1 2014, up from 11 in Q4 2013.
- Funds reported $3.97M of Rosetta Genomics Ltd. stock for Q1 2014, up 734% quarter-over-quarter.
- 11 funds opened new Rosetta Genomics Ltd. positions in Q1 2014 and 4 closed out, a net change of +7 holders.
- The largest Rosetta Genomics Ltd. buyer in Q1 2014 was B. Riley Wealth Advisors, an estimated $1.59M added.
- The largest Rosetta Genomics Ltd. seller in Q1 2014 was Tower Research Capital (TRC), an estimated $162K sold.
Based on aggregated 13F filings for Q1 2014.